---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004136"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-14T13:00:38+00:00"
generated_at: "2026-08-14T13:02:11.477080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated

## Summary
- Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.
- Six-month net loss $6.3M vs $4.2M; cash $2.2M at June 30, down from $6.0M.
- Closed Aug 13 public offering gross $2.5M, net $2.1M; equity est. $3.2M, restoring Nasdaq compliance.
- Phase 2/3 SIL204 trial initiated July 29 at Tel Aviv Sourasky; approvals from Germany BfArM and Israel.
- 1-for-10 reverse split May 28, 2026; preclinical data supports immune-sensitization across 4 KRAS mutations.

## SEC filing metadata
- accession: 0001178913-26-004136
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-14T13:00:38+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/0001178913-26-004136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/zk2635972.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004136
- JSON: https://secwatch.observer/filing/0001178913-26-004136.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.